Pharmas risk losing doctors to digital fatigue in the post-COVID-19 world if they don’t get their email strategy rightnews2022-04-19T12:34:00+00:00April 19th, 2022|Fierce Pharma|
For Incyte’s eczema cream Opzelura, consumer complaint reveals ongoing quality woes, replacement backlognews2022-04-19T11:34:35+00:00April 19th, 2022|Fierce Pharma|
J&J taps tiny Bioasis for tech to cross blood-brain barriernews2022-04-19T09:23:08+00:00April 19th, 2022|Fierce Pharma|
Surf’s up: Startup stoked as Chris Garabedian fund funnels cash into ultra-rapid insulin programnews2022-04-19T09:14:28+00:00April 19th, 2022|Fierce Pharma|
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030news2022-04-18T19:18:07+00:00April 18th, 2022|Fierce Pharma|
Johnson & Johnson inks $99M opioid settlement with West Virginia: reportnews2022-04-18T18:35:20+00:00April 18th, 2022|Fierce Pharma|
Oft-chided Lupin dinged by FDA at Indian pharmaceutical ingredients plantnews2022-04-18T17:45:39+00:00April 18th, 2022|Fierce Pharma|
Biden administration official says Americans over 60 should get second COVID boosternews2022-04-18T15:21:21+00:00April 18th, 2022|Fierce Pharma|
BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe?news2022-04-18T15:09:29+00:00April 18th, 2022|Fierce Pharma|
Bayer CEO gets proxy brawlers’ backing, but exec compensation still in investors’ crosshairs: reportnews2022-04-18T15:01:26+00:00April 18th, 2022|Fierce Pharma|
